Neuphoria Therapeutics Inc (NEUP) - Net Assets
Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has net assets worth $29.70 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($36.60 Million) and total liabilities ($6.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Neuphoria Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.70 Million |
| % of Total Assets | 81.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | -19.26% |
| 10-Year Change | -8.89% |
| Growth Volatility | 72.25 |
Neuphoria Therapeutics Inc - Net Assets Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore NEUP total asset value for the complete picture of this company's asset base.
Annual Net Assets for Neuphoria Therapeutics Inc (1999–2025)
The table below shows the annual net assets of Neuphoria Therapeutics Inc from 1999 to 2025. For live valuation and market cap data, see market cap of Neuphoria Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $28.87 Million | +65.08% |
| 2024-06-30 | $17.49 Million | +19.37% |
| 2023-06-30 | $14.65 Million | -62.58% |
| 2022-06-30 | $39.15 Million | +9.48% |
| 2021-06-30 | $35.76 Million | +310.39% |
| 2020-06-30 | $8.71 Million | -29.70% |
| 2019-06-30 | $12.39 Million | -0.50% |
| 2018-06-30 | $12.46 Million | -59.93% |
| 2017-06-30 | $31.09 Million | -1.90% |
| 2016-06-30 | $31.69 Million | +29.25% |
| 2015-06-30 | $24.52 Million | -41.90% |
| 2014-06-30 | $42.20 Million | +11.67% |
| 2013-06-30 | $37.79 Million | +42.57% |
| 2012-06-30 | $26.51 Million | -13.59% |
| 2011-06-30 | $30.67 Million | +41.72% |
| 2010-06-30 | $21.64 Million | +43.45% |
| 2009-06-30 | $15.09 Million | -26.75% |
| 2008-06-30 | $20.60 Million | +6.98% |
| 2007-06-30 | $19.25 Million | +137.02% |
| 2006-06-30 | $8.12 Million | -0.25% |
| 2005-06-30 | $8.14 Million | +30.41% |
| 2004-06-30 | $6.24 Million | +38.00% |
| 2003-06-30 | $4.52 Million | -19.54% |
| 2002-06-30 | $5.62 Million | +8.18% |
| 2001-06-30 | $5.20 Million | +72.00% |
| 2000-06-30 | $3.02 Million | +930.72% |
| 1999-06-30 | $-363.81K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuphoria Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27036516900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.87 | 0.00% |
| Other Comprehensive Income | $-4.32 Million | -14.97% |
| Other Components | $304.18 Million | 1053.51% |
| Total Equity | $28.87 Million | 100.00% |
Neuphoria Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aspermont Ltd
AU:ASP
|
$23.29 Million |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
$23.29 Million |
|
Master Pack Group Bhd
KLSE:7029
|
$23.31 Million |
|
Minnova Corp
V:MCI
|
$23.31 Million |
|
Minho M Bhd
KLSE:5576
|
$23.29 Million |
|
Pergamon Status Dis Ticaret AS
IS:PSDTC
|
$23.28 Million |
|
Alcom Group Bhd
KLSE:2674
|
$23.27 Million |
|
SIAV S.P.A.
F:F4U
|
$23.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuphoria Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,490,000 to 28,872,510, a change of 11,382,510 (65.1%).
- Net loss of 565,773 reduced equity.
- Other comprehensive income decreased equity by 1,308,793.
- Other factors increased equity by 13,257,076.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-565.77K | -1.96% |
| Other Comprehensive Income | $-1.31 Million | -4.53% |
| Other Changes | $13.26 Million | +45.92% |
| Total Change | $- | 65.08% |
Book Value vs Market Value Analysis
This analysis compares Neuphoria Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.29x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-06-30 | $-1.45 | $5.22 | x |
| 2000-06-30 | $2.46 | $5.22 | x |
| 2001-06-30 | $2.19 | $5.22 | x |
| 2002-06-30 | $1.84 | $5.22 | x |
| 2003-06-30 | $1.35 | $5.22 | x |
| 2004-06-30 | $1.54 | $5.22 | x |
| 2005-06-30 | $1.51 | $5.22 | x |
| 2006-06-30 | $0.63 | $5.22 | x |
| 2007-06-30 | $1.28 | $5.22 | x |
| 2008-06-30 | $1.10 | $5.22 | x |
| 2009-06-30 | $0.75 | $5.22 | x |
| 2010-06-30 | $0.86 | $5.22 | x |
| 2011-06-30 | $1.14 | $5.22 | x |
| 2012-06-30 | $0.92 | $5.22 | x |
| 2013-06-30 | $1.21 | $5.22 | x |
| 2014-06-30 | $1.21 | $5.22 | x |
| 2015-06-30 | $0.70 | $5.22 | x |
| 2016-06-30 | $0.83 | $5.22 | x |
| 2017-06-30 | $0.77 | $5.22 | x |
| 2018-06-30 | $0.31 | $5.22 | x |
| 2019-06-30 | $0.29 | $5.22 | x |
| 2020-06-30 | $0.19 | $5.22 | x |
| 2021-06-30 | $0.55 | $5.22 | x |
| 2022-06-30 | $0.35 | $5.22 | x |
| 2023-06-30 | $0.12 | $5.22 | x |
| 2024-06-30 | $0.12 | $5.22 | x |
| 2025-06-30 | $17.79 | $5.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuphoria Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.36%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.50x
- Recent ROE (-1.96%) is above the historical average (-53.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-188.58K |
| 2000 | -28.03% | 0.00% | 0.00x | 1.05x | $-1.15 Million |
| 2001 | -32.19% | -279.37% | 0.11x | 1.06x | $-2.19 Million |
| 2002 | -34.94% | -216.54% | 0.10x | 1.59x | $-2.53 Million |
| 2003 | -67.62% | -441.62% | 0.08x | 1.87x | $-3.51 Million |
| 2004 | -77.86% | -1657.63% | 0.03x | 1.68x | $-5.49 Million |
| 2005 | -59.70% | -1657.63% | 0.02x | 1.60x | $-5.68 Million |
| 2006 | -67.26% | -827.28% | 0.05x | 1.80x | $-6.28 Million |
| 2007 | -26.20% | -668.10% | 0.03x | 1.36x | $-6.97 Million |
| 2008 | -21.67% | -511.31% | 0.03x | 1.32x | $-6.52 Million |
| 2009 | -41.86% | -353.20% | 0.09x | 1.32x | $-7.82 Million |
| 2010 | -39.60% | -503.29% | 0.06x | 1.24x | $-10.73 Million |
| 2011 | -28.11% | -293.61% | 0.08x | 1.20x | $-11.69 Million |
| 2012 | -12.05% | -59.77% | 0.17x | 1.20x | $-5.85 Million |
| 2013 | -29.35% | -444.13% | 0.05x | 1.29x | $-14.87 Million |
| 2014 | 7.41% | 16.70% | 0.31x | 1.45x | $-1.09 Million |
| 2015 | -75.68% | -254.11% | 0.14x | 2.16x | $-21.01 Million |
| 2016 | -51.07% | -207.75% | 0.12x | 2.07x | $-19.35 Million |
| 2017 | -21.38% | -36.58% | 0.28x | 2.08x | $-9.76 Million |
| 2018 | -211.90% | -668.33% | 0.08x | 3.84x | $-27.64 Million |
| 2019 | -85.51% | -1477.09% | 0.02x | 3.03x | $-11.84 Million |
| 2020 | -79.02% | -15255.78% | 0.00x | 2.72x | $-7.76 Million |
| 2021 | -24.18% | -931.70% | 0.02x | 1.14x | $-12.22 Million |
| 2022 | -58.58% | -8253.62% | 0.01x | 1.15x | $-26.85 Million |
| 2023 | -147.75% | 0.00% | 0.00x | 1.32x | $-23.11 Million |
| 2024 | -132.61% | 0.00% | 0.00x | 1.58x | $-24.94 Million |
| 2025 | -1.96% | -2.36% | 0.55x | 1.50x | $-3.45 Million |
Industry Comparison
This section compares Neuphoria Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuphoria Therapeutics Inc (NEUP) | $29.70 Million | 0.00% | 0.23x | $23.29 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more